Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 3, 2015, Pages 395-405

  Wang, Jianlin ^a   Yang, Hao ^a   Li, Wenjie ^a   Xu, Huibi ^a   Yang, Xiangliang ^a   Gan, Lu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Drug resistance; FOXO1; Ovarian cancer cells; ROS; Trx1

Indexed keywords

PACLITAXEL; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 1; TRANSCRIPTION FACTOR FKHR; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; THIOREDOXIN; TUMOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; GENE INTERACTION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MUTANT; OVARY CANCER; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; AMINO ACID SUBSTITUTION; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; MISSENSE MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MUTATION, MISSENSE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84929959648     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.12.002     Document Type: Article

References (43)

1. Vasey P.A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer 2003, 89:S23-S28.
2. Salehan M.R., Morse H.R. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br. J. Biomed. Sci. 2013, 70:31-40.
3. Wu C.P., Hsieh C.H., Wu Y.S. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol. Pharm. 2011, 8:1996-2011.
4. Duan Z., Brakora K.A., Seiden M.V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 2004, 3:833-838.
5. Karnak D., Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr. Drug Targets 2010, 11:699-707.
6. Ahsan M.K., Lekli I., Ray D., Yodoi J., Das D.K. Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart. Antioxid. Redox Signal. 2009, 11:2741-2758.
7. Baker A., Payne C.M., Briehl M.M., Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 1997, 57:5162-5167.
8. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 1996, 16:3459-3466.
9. Kalinina E.V., Chernov N.N., Saprin A.N., Kotova Y.N., Gavrilova Y.A., Chermnykh N.S., Shcherbak N.P. Expression of genes for thioredoxin 1 and thioredoxin 2 in multidrug resistance ovarian carcinoma cells SKVLB. Bull. Exp. Biol. Med. 2007, 144:301-303.
10. Grogan T.M., Fenoglio-Prieser C., Zeheb R., Bellamy W., Frutiger Y., Vela E., Stemmerman G., Macdonald J., Richter L., Gallegos A., Powis G. Thioredoxin, a puntative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 2000, 31:475-481.
11. Li C., Thompson M.A., Tamayo A.T., Zuo Z., Lee J., Vega F., Ford R.J., Pham L.V. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget 2012, 3:314-326.
12. Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M., Kohno K., Takenaka K., Sugimachi K., Kuwano M. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 1996, 56:5330-5333.
13. Kim S.J., Miyoshi Y., Taguchi T., Tamaki Y., Nakamura H., Yodoi J., Kato K., Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 2005, 11:8425-8430.
14. Raffel J., Bhattacharyya A.K., Gallegos A., Cui H., Einspahr J.G., Alberts D.S., Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 2003, 142:46-51.
15. Powis G., Kirkpatrick D.L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007, 7:392-397.
16. Schenk H., Klein M., Erdbrügger W., Dröge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1672-1676.
17. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
18. Meuillet E.J., Mahadevan D., Berggren M., Coon A., Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch. Biochem. Biophys. 2004, 429:123-133.
19. Huang H., Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 2007, 120:2479-2487.
20. Lu H., Huang H. FOXO1: a potential target for human diseases. Curr. Drug Targets 2011, 12:1235-1244.
21. Gomes A.R., Brosens J.J., Lam E.W. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008, 7:3133-3136.
22. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., Brosens J.J., Lam E.W. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 2008, 7:670-678.
23. Han C.Y., Cho K.B., Choi H.S., Han H.K., Kang K.W. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008, 29:1837-1844.
24. Goto T., Takano M., Hirata J., Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br. J. Cancer 2008, 98:1068-1075.
25. Gan L., Liu P., Lu H., Chen S., Yang J., McCarthy J.B., Knudsen K.E., Huang H. Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death Differ. 2009, 16:1408-14179.
26. 2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cells. Cancer Res. 2007, 67:10067-10077.
27. Arner E.S., Zhong L., Holmgren A. Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol. 1999, 300:226-239.
28. 2+-channels in guard cells requires cytosolic NAD(P)H and is differentially disrupted upstream and downstream of reactive oxygen species production in abi1-1 and abi2-1 protein phosphatase 2C mutants. Plant Cell 2001, 13:2513-2523.
29. Alili L., Sack M., von Montfort C., Giri S., Das S., Carroll K.S., Zanger K., Seal S., Brenneisen P. Downregulation of tumor growth and invasion by redox-active nanoparticles. Antioxid. Redox Signal. 2013, 19:765-778.
30. Zhao H., Joseph J., Fales H.M., Sokoloski E.A., Levine R.L., Vasquez-Vivar J., Kalyanaraman B. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5727-5732.
31. Hanelt M., Gareis M., Kollarczik B. Cytotoxicity of mycotoxins evaluated by the MTT-cell culture assay. Mycopathologia 1994, 128:167-174.
32. Gan L., Wang J., Xu H., Yang X. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 2011, 71:1158-1166.
33. Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A., Simon J.A., Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 2010, 12:1108-1114.
34. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., Gan L., Xu H., Yang X. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
35. Mitsushita J., Lambeth J.D., Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res. 2004, 64:3580-3585.
36. Go Y.M., Orr M., Jones D.P. Increased nuclear thioredoxin-1 potentiates cadmium-induced cytotoxicity. Toxicol. Sci. 2013, 131:84-94.
37. Haendeler J., Hoffmann J., Tischler V., Berk B.C., Zeiher A.M., Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat. Cell Biol. 2002, 4:743-749.
38. Schroeder P., Popp R., Wiegand B., Altschmied J., Haendeler J. Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells-important role for nuclear thioredoxin-1. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2325-2331.
39. Pillai C.K., Pillai K.S. Antioxidants in health. Int. J. Physiol. Pharmacol. 2002, 46:1-5.
40. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3:420-425.
41. Benhar M., Dalyot I., Engelberg D., Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 2001, 21:6913-6926.
42. Wondrak G.T. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox Signal. 2009, 11:3013-3069.
43. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.